Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c
July 27, 2017 4:45 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.01 better than the analyst estimate of ($1.73).
Cash, cash equivalents, and investments were $457.5 million as of June 30, 2017.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More